葡萄糖脑苷酶
表型
LRRK2
疾病
生物
神经炎症
基因型
机制(生物学)
遗传学
内质网
生物信息学
基因
医学
突变
内科学
哲学
认识论
作者
Konstantin Senkevich,Uladzislau Rudakou,Ziv Gan‐Or
出处
期刊:Handbook of Clinical Neurology
[Elsevier BV]
日期:2023-01-01
卷期号:: 155-170
被引量:7
标识
DOI:10.1016/b978-0-323-85555-6.00016-3
摘要
Genetic variants in GBA, encoding the lysosomal enzyme glucocerebrosidase (GCase), are common risk factors for Parkinson's disease (PD). Genotype-phenotype studies have demonstrated that different types of GBA variants have differential effects on the phenotype. Variants could be classified as mild or severe depending on the type of Gaucher disease they cause in the biallelic state. It was shown that severe GBA variants, as compared to mild variants, are associated with higher risk of PD, earlier age at onset, and faster progression of motor and nonmotor symptoms. The observed difference in phenotype might be caused by a diversity of cellular mechanisms related to the particular variants. The lysosomal function of GCase is thought to play a significant role in the development of GBA-associated PD, and other mechanisms such as endoplasmic reticulum retention, mitochondrial dysfunction, and neuroinflammation have also been suggested. Moreover, genetic modifiers such as LRRK2, TMEM175, SNCA, and CTSB can either affect GCase activity or modulate risk and age at onset of GBA-associated PD. To achieve ideal outcomes with precision medicine, therapies will have to be tailored to individuals with specific variants, potentially in combination with known modifiers.
科研通智能强力驱动
Strongly Powered by AbleSci AI